Subscribe to RSS
DOI: 10.1055/s-0039-1681336
COMPARISON OF THE EFFECTIVENESS OF FOUR BOWEL CLEANSING PREPARATIONS BEFORE COLONOSCOPY – RANDOMIZED, SINGLE – BLIND STUDY
Publication History
Publication Date:
18 March 2019 (online)
Aims:
The aim of the study is to compare the effectiveness of bowel cleansing preparations. Polyethylene glycol (PEG) as a gold standard of bowel cleansing and low – volume solutions: sulphate-based solution (SBS), low-volume PEG + ascorbic acid (2L-PEG/Asc) and sodium picosulfate + magnesium citric-acid solution (SP/MC).
Methods:
Randomized, single-blind study. Patients with colonoscopy from all indications (except planned therapeutic procedure) has been recruited. Instructions have been provided orally and in printed version with split-dose regimen recommended. The bowel cleansing quality has been evaluated by the experienced endoscopists blinded to the type of a bowel preparation. The effectiveness has been assessed by the degree of bowel cleansing according to Boston Bowel Preparation Scale (BBPS) and polyp detection rate (PDR). Interim analysis presented.
Results:
In the period 09/2017 till 09/2018 304 individuals were included. Split-dose regimen was respected in 84,2%. Adequate bowel cleansing (BBPS total score ≥6 and sub score ≥2 in each colonic segment) was comparable for all groups (96,1% PEG; 94,5% SBS; 93,5% 2L-PEG/Asc; 93,6% SP/MC; p = 0,912). Excellent bowel cleansing (BBPS total score ≥8 and sub score ≥2 in each colonic segment) was significantly often in PEG and SBS group (90,8% PEG; 86,3% SBS; 75,3% 2L-PEG/Asc; 76,9% SP/MC; p = 0,031). Polyp detection rate was comparable for all groups (48,7% PEG; 48,0% SBS group; 40,3% 2L-PEG/Asc; 41,0% SP/MC; p = 0,610).
Conclusions:
The interim results show the comparable efficiency of bowel preparation for all four tested solutions. Low volume solutions could be appropriate alternative of polyethylene glycol. The results need to be verified on larger set of individuals. Target number of individuals for the study is 400.
Supported by the projects MO1012 a Progres Q28/LF1. The study is registered on ClinicalTrials.gov.(NCT03242369).
#